"Infertility treatment heads first drugs on FDA’s new priority review scheme" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.

The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...

Eydenzelt is approved for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema ...

After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...

Regeneron Pharmaceuticals (NASDAQ: REGN) has outperformed the market over the past 20 years by 12.6% on an annualized basis producing an average annual return of 21.67%. Currently, Regeneron ...

Xeris Biopharma’s strong Q2 FY2025 results, driven by Recorlev’s growth. Learn how shifting product mix boosts XERS stock's ...

Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.

The 2025 Annual Congress of the European Society for Medical Oncology (ESMO) featured a track on tumor-agnostic therapies – the first time such a track has been included at ESMO, or at any major ...

From STAT’s Adam Feuerstein: Let’s start with Replimune, which said this morning the Food and Drug Administration will review ...